BioMarin Raises 2025 Revenue Guidance as PALYNZIQ and VOXZOGO Sales Climb 20%
BioMarin Pharmaceutical Inc. reported operating cash flows totaling $369 million for the third quarter of 2025, and $728 million in year-to-date operating cash flows. Total cash, cash equivalents, and investments were $2.0 billion as of September 30, 2025, compared to $1.66 billion at December 31, 2024. The company updated its 2025 full-year financial guidance to reflect acquired in-process research and development charges of $221 million on a pre-tax basis related to the acquisition of Inozyme. The company also revised its Non-GAAP Operating Margin and Non-GAAP Diluted EPS guidance to include the impact of these charges. Weighted-average diluted shares outstanding for Non-GAAP Diluted EPS guidance is approximately 200 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF07455) on October 27, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。